L’infertilité masculine: témoignage d’un Fils Distilbène, récit d’un parcours en PMA
Récit d’un parcours en PMA, Procréation Micalement Assistée
” L’idée d’écrire un livre sur notre parcours PMA est née dès les premières semaines de traitement à l’hôpital de Poissy. Notre médecin nous avait expliqué que l’annonce de la stérilité était mal prise en compte en France, et qu’il faudrait pouvoir changer ça. J’ai tout de suite pensé que le témoignage sous forme d’un livre pouvait y contribuer.
Mon épouse m’a encouragé tout au long de notre parcours, à la seule condition : ce livre ne verrait le jour que si nous réussissions à devenir parents. Sa publication, aujourd’hui, est donc chargée de sens pour nous, à l’instant où j’écris ces quelques livres.
C’est donc chose faite : le livre est en ligne !
lundi 20 février 2012 – Christophe Coupez, fils distilbène ”
Scientists developing model that predicts drug side effects in different patients
2015 Study Summary
Understanding individual variation is fundamental to personalized medicine. Yet interpreting complex phenotype data, such as multi-compartment metabolomic profiles, in the context of genotype data for an individual is complicated by interactions within and between cells and remains an unresolved challenge. Here, we constructed multi-omic, data-driven, personalized whole-cell kinetic models of erythrocyte metabolism for 24 healthy individuals based on fasting-state plasma and erythrocyte metabolomics and whole-genome genotyping. We show that personalized kinetic rate constants, rather than metabolite levels, better represent the genotype. Additionally, changes in erythrocyte dynamics between individuals occur on timescales of circulation, suggesting detected differences play a role in physiology. Finally, we use the models to identify individuals at risk for a drug side effect (ribavirin-induced anemia) and how genetic variation (inosine triphosphatase deficiency) may protect against this side effect. This study demonstrates the feasibility of personalized kinetic models, and we anticipate their use will accelerate discoveries in characterizing individual metabolic variation.
Sources and more information
Personalized Whole-Cell Kinetic Models of Metabolism for Discovery in Genomics and Pharmacodynamics, sciencedirect, doi:10.1016/j.cels.2015.10.003, 28 October 2015.
Researchers are on their way to predicting what side effects you’ll experience from a drug, University of California, November 2, 2015.
Scientists developing model that predicts drug side effects in different patients, medicalnewstoday, 3 November 2015.
This post content is published by CHEM Trust, Protecting people and the environment from harmful hormone/endocrine disrupting chemicals (EDCs) at the UK, EU and international level.
Glyphosate: The WHO says it’s probably carcinogenic, but what about the EU?
In March, the World Health Organisation classified the widely-used herbicide Glyphosate as a probable carcinogen. CHEM Trust has joined with over 45 organisations to send a letter to EU Health Commissioner Vytenis Andriukaitis, urging him to take precautionary action on the use of glyphosate, given these ongoing discussions regarding its carcinogenic properties.
In the letter we express our concern about an assessment for the renewal of glyphosate’s EU authorisation which has been produced by the German Federal Institute for Risk Assessment (BfR), which has been criticised for downplaying positive findings of carcinogenicity. The BfR report aims to form the basis for a re-approval of glyphosate in Europe, as the current authorization expires this year and has recently been extended to June 2016. However, EU pesticide law states that pesticide active substances which are classified as carcinogenic under EU law should not be approved for use.
The letter calls on the Health Commissioner to:
Ask the European Chemicals Agency (ECHA) to carry out a thorough analysis of glyphosate’s carcinogenicity and other relevant endpoints as part of its forthcoming assessment of the harmonised classification and labelling of this substance;
Ensure that the peer review of the BfR report by the European Food Safety Authority (EFSA) is scientifically robust and credible, incorporating the outcome of the harmonised classification and labelling;
Immediately impose a ban on the use of glyphosate in applications where it results in the greatest public and worker exposure, either directly or through residues in food.
“Given our widespread exposure to glyphosate, the WHO’s classification of glyphosate as probable carcinogen is highly concerning. Several shops have already started taking products with glyphosate from their shelves. When will the Commission get active and take precautionary measures to protect our health?”
Drug makers accused of trying to hide test results
Pharmaceutical companies are lobbying to block the public release of clinical trial data in a move that campaigners say puts patient safety at risk.
A European transparency initiative is proposed to ensure that when regulators approve new drugs the full data from the trials would be publicly released, rather than just a summary published in a medical journal.
The proposal comes after high-profile cases in which independent researchers found that drugs such as Tamiflu or the antidepressant Seroxat were more dangerous or less effective than pharmaceutical companies had claimed.
Continue reading Drug makers accused of trying to hide test results, thetimes, October 27 2015.
Si dans environ 33% des cas, l’infertilité a une cause purement féminine, dans 21% des cas, elle implique seulement l’homme. Mais cette stérilité masculine est encore un sujet tabou dans notre société. Pour beaucoup, elle représente une honte et est synonyme d’émasculation. Pourtant, ce problème n’est pas nécessairement accompagné de troubles sexuels et n’a pas de rapport direct avec la virilité. Christophe Coupez, fils distilbène, a décidé de lever le voile sur son infertilité en écrivant un livre : Père malgré tout.
While it is known that sperm aneuploidy contributes to early pregnancy losses and congenital abnormalities, causes are unknown and environmental contaminants are suspected.
Our goal was to evaluate associations between lifetime exposure to organochlorines, specifically dichlorodiphenyldicholorethylene (p,p’-DDE) and polychlorinated biphenyls (PCBs) and sperm aneuploidy in men from the general population of the Faroe Islands, a population with a known history of organochlorine exposures.
Serum and semen samples from men (n=90) ages 22-44 participating in Faroe Islands health studies were analyzed for p,p’-DDE and PCB (118, 138, 153, and 180) and adjusted for total lipids. Cord blood and age 14 serum were available for a subgroup (n=40) and also analyzed for p,p’-DDE and PCBs. Sperm fluorescence in situ hybridization (FISH) for chromosome X, Y, and 18 was used to determine rates of XX18, XY18, YY18 and total disomy. Multivariable adjusted Poisson models were used to estimate the relation between organochlorine exposure and sperm disomy outcomes.
Adult p,p’-DDE and total PCB serum concentrations were each associated with significantly increased rates of XX18, XY18 and total disomy. Age 14 p,p’-DDE and PCB concentrations were each associated with significantly increased rates of XX, XY and total disomy at adult age. Associations between cord blood concentrations of p,p’-DDE and PCBs and sperm disomy at adult age were not consistently significant.
Organochlorine exposures measured at age 14 and in adulthood were associated with sperm disomy in this sample of high exposure men, suggesting the impacts of persistent pollutants on testicular maturation and function need deeper investigation.
Sperm Aneuploidy in Faroese Men with Lifetime Exposure to Dichlorodiphenyldichloroethylene (DDE) and Polychlorinated Biphenyl (PCB) Pollutants, Environmental Health Perspectives; DOI:10.1289/ehp.1509779, 4 November 2015.
The National Cooperative Diethylstilbestrol Adenosis (DESAD) Project has completed the major portion of its enrollment phase with the examination of more than 3000 daughters of women taking synthetic nonsteroidal estrogens (denoted diethylstilbestrol DES) during pregnancies occurring from the early 1940s to the mid-1960s.
The aims of the Project are to fill urgent needs for information on the prevalence and incidence of structural and epithelial abnormalities or neoplastic changes and their complications in these young women.
Participants are grouped by mode of entry as identified by prenatal record review (40.1%), documented as DES-exposed but walking in (25.1%), or referred (22.8%) to the DESAD Project for examination, and not documented as exposed but having gynecologic abnormalities typical of those associated with DES exposure (12.0%).
This study cohort, in part having paired controls, will be examined annually for at least 5 years. Details of the design and selected preliminary findings are reported.
Sources and more information
Design and preliminary observations of National Cooperative Diethylstilbestrol Adenosis (DESAD) Project, Obstetrics and Gynecology 1978 Apr;51(4):453-8, NCBI PMID: 662228.